Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The table above records the past week's changes to the progress of selected potential new products through the clinical trial pipeline, using data from Informa Pharma Intelligence's Biomedtracker. It lists drugs for which an important event was recorded between 15 October and 21 October, divided by event type.
Hyperlinks in the table take subscribers to the relevant event section of Biomedtracker where more details can be found, or...
Screaming is a powerful human behavior with deep evolutionary roots. Turning up the volume affects our bodies and brains in surprising ways, influencing stress, communication, and even group dynamics. Understanding the science behind screaming reveals its complex role in both health and society.
We may then state the above equation in this way: The work done by the resultant force acting on a particle is equal to the change in the kinetic energy of the particle.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
